{
    "clinical_study": {
        "@rank": "156459", 
        "arm_group": [
            {
                "arm_group_label": "Serelaxin", 
                "arm_group_type": "Experimental", 
                "description": "48 hour infusion of serelaxin every 4 weeks for 3 doses"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "48 hour infusion of placebo every 4 weeks for 3 doses"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety of repeat doses of serelaxin in chronic\n      heart failure.  At the same time, markers of efficacy will also be collected as exploratory\n      measures."
        }, 
        "brief_title": "Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight of \u2264 160 kg.\n\n          -  Subjects with compensated CHF (NYHA Class II - III) at time of screening with a prior\n             documented history of chronic heart failure.\n\n          -  NT-proBNP >300 pg/ml (according to central measurement) at visit 1.\n\n          -  Subjects treated with appropriate and guideline-indicated CHF standard of care.\n\n          -  Ability to comply with all requirements, including ability to receive at least a 48\n             hour infusion plus follow-up time required for each dosing visit.\n\n        Exclusion Criteria:\n\n          -  Current acute decompensated HF\n\n          -  Any major solid organ transplant recipient or planned anticipated organ transplant\n             within 1 year.\n\n          -  Documented history of untreated ventricular arrhythmia with syncopal episodes,\n             ventricular tachycardia, or ventricular fibrillation without ICD (implantable\n             cardioverter defibrillator) with significant hemodynamic consequences within the 3\n             months prior to screening.\n\n          -  Presence of hemodynamically significant mitral and /or aortic valve disease, except\n             mitral regurgitation secondary to left ventricular dilatation: including significant\n             left ventricular outflow obstruction (e.g., obstructive hypertrophic cardiomyopathy,\n             severe aortic stenosis)\n\n          -  Subjects with severe renal impairment defined as pre-randomization eGFR < 30\n             ml/min/1.73m2 calculated using the sMDRD equation and/or those receiving current or\n             planned dialysis or ultrafiltration\n\n        Other protocol defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982292", 
            "org_study_id": "CRLX030A2209", 
            "secondary_id": "2013-002781-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "Serelaxin", 
                "description": "A continuous 48 hour infusion of serelaxin administered every 4 weeks for a total of 3 doses.", 
                "intervention_name": "Serelaxin", 
                "intervention_type": "Drug", 
                "other_name": "RLX030"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "A continuous 48 hour infusion of placebo administered every 4 weeks for a total of 3 doses.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Chronic Heart Failure, CHF, Heart Failure, HF, Immunogenicity, Anti-bodies, Hypersensitivity, Serelaxin", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80918"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80228"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32216"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Macon", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31201"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miinneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55417"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599-7075"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298-0050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland", 
                        "zip": "20520"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13125"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01069"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60488"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greifswald", 
                        "country": "Germany", 
                        "zip": "17475"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grunstadt", 
                        "country": "Germany", 
                        "zip": "D-67269"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30159"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24105"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Luebeck", 
                        "country": "Germany", 
                        "zip": "23562"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "zip": "39112"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cortona", 
                        "country": "Italy", 
                        "state": "AR", 
                        "zip": "52044"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "state": "BS", 
                        "zip": "25123"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MB", 
                        "zip": "20900"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vimercate", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "200059"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0424"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "121552"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117198"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "29010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "state": "Galicia", 
                        "zip": "15706"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "141 86"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Diskapi / Ankara", 
                        "country": "Turkey", 
                        "zip": "06110"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haydarpasa/Istanbul", 
                        "country": "Turkey", 
                        "zip": "34668"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kocaeli", 
                        "country": "Turkey", 
                        "zip": "41380"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meselik / Eskisehir", 
                        "country": "Turkey", 
                        "zip": "26480"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sivas", 
                        "country": "Turkey", 
                        "zip": "58140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Finland", 
                "Germany", 
                "Italy", 
                "Norway", 
                "Russian Federation", 
                "Spain", 
                "Sweden", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of participants with chronic heart failure (CHF) who develop anti-serelaxin antibodies at any time following repeat administration of IV continuous infusions of serelaxin administered for up to 48 hours", 
            "safety_issue": "Yes", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with chronic heart failure who develop anti-serelaxin antibodies after a single infusion (Week 4), two infusions (Week 8) or three infusions (Week 12) of serelaxin.", 
                "safety_issue": "Yes", 
                "time_frame": "Week 4, Week 8, Week 12"
            }, 
            {
                "measure": "Antibody levels in subjects with chronic heart failure who develop anti-serelaxin antibodies (neutralizing, non-neutralizing or both) at any time following 3 repeated infusions and at Week 4, Week 8 and Week 12.", 
                "safety_issue": "Yes", 
                "time_frame": "Week 4, Week 8, Week 12"
            }, 
            {
                "description": "Incidence rate of adverse events, including serious adverse events, death, and overall, which occur during and after administration of repeated infusions of serelaxin relative to placebo in subjects with chronic heart failure will be reported.", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Characterization of the pharmacokinetics of serelaxin during and after drug administration of repeated infusions.", 
                "measure": "Pharmacokinetics of RLX030: Area under the plasma concentration time curve from time zero up to 48 hours post dose (AUC 0-48)", 
                "safety_issue": "No", 
                "time_frame": "pre-infusion and 8, 24 and 48 hours post each infusion."
            }, 
            {
                "measure": "Percentage of participants with chronic heart failure who develop neutralizing or non-neutralizing anti-serelaxin antibodies at any time following 3 repeated infusions and at Week 4, Week 8, and Week 12", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Pharmacokinetics of RLXL030: actual concentrations over time", 
                "safety_issue": "No", 
                "time_frame": "pre-infusion and 8, 24, and 48 hours post each infusion"
            }, 
            {
                "measure": "Pharmacokinetics of RLX030: Cmax steady state (Cmaxss) concentration at 48 hours", 
                "safety_issue": "No", 
                "time_frame": "48 hours post each infusion"
            }, 
            {
                "measure": "Pharmacokinetics of RLX030: clearance of serelaxin", 
                "safety_issue": "No", 
                "time_frame": "48 hours after every infusion"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}